Natalizumab Bojian Pharmaceuticals

Natalizumab is approved to treat relapsing-remitting multiple sclerosis and Crohn's disease. It is usually used in patients who have failed first-line treatment, It must be used in conjunction with the TOUCH program, a national risk minimization program designed to "minimize the risk of progressive multifocal leukoencephalopathy (PML)risks, minimizing death and disability due toPML and promoting informed risk-benefit decisions regarding the use of natalizumab. This drug is being studied in ulcerative colitis.

Natalizumab treatment should be initiated and supervised by a doctor who is experienced in treating neurological disorders and who has access to a magnetic resonance imaging (MRI) scanner, which will allow doctors to check for changes in the brain or spinal cord associated with multiple sclerosis or a brain infection called progressive multifocal leukoencephalopathy, which is associated with natalizumab and other MS drugs. Natalizumab is administered intravenously every 4 weeks for 1 hour. Because infusions may trigger allergic reactions, patients must be monitored during and for 1 hour after the infusion. If the patient does not see significant benefit after 6 months, the physician should reassess the treatment. NatalizumabThis drug is only available with a prescription.

Natalizumab's original patent drug is not on the market in China and cannot be included in medical insurance. Therefore, there is no natalizumab produced by Bojian Pharmaceuticals, and the drug is temporarily unavailable in domestic hospitals and pharmacies. Currently, the generic drug natalizumab on the market overseas may cost more than 8,000 US dollars per box (the price may fluctuate due to exchange rates), which is very expensive. For more drug information and specific prices, please consult Yaode Medical Consultant.